Compare METC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | ALLO |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.3M | 722.1M |
| IPO Year | 2016 | 2018 |
| Metric | METC | ALLO |
|---|---|---|
| Price | $14.01 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $34.00 | $8.35 |
| AVG Volume (30 Days) | 2.3M | ★ 4.9M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.61 | N/A |
| Revenue Next Year | $11.96 | $142,416.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.56 | $1.04 |
| 52 Week High | $57.80 | $4.46 |
| Indicator | METC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 47.44 |
| Support Level | $13.35 | $1.87 |
| Resistance Level | $16.20 | $2.25 |
| Average True Range (ATR) | 0.97 | 0.12 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 82.02 | 17.74 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).